Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma

Journal of Clinical Oncology

Volumn 24, Issue 30, 2006, Pages 4867-4874

  Fisher, Richard I ^a   Bernstein, Steven H ^b   Kahl, Brad S ^b   Djulbegovic, Benjamin ^b   Robertson, Michael J ^b   De Vos, Sven ^b   Epner, Elliot ^b   Krishnan, Amrita ^b   Leonard, John P ^b   Lonial, Sagar ^b   Stadtmauer, Edward A ^b   O'Connor, Owen A ^b   Shi, Hongliang ^b   Boral, Anthony L ^b   Goy, André ^b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; BORTEZOMIB; IMMUNOLOGIC AGENT; MITOXANTRONE; RITUXIMAB; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DISABILITY; DISEASE COURSE; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCULOSKELETAL PAIN; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; SEPSIS; STEM CELL TRANSPLANTATION; SYNCOPE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; WEAKNESS; DRUG RESISTANCE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PYRAZINES; TREATMENT OUTCOME;

EID: 33750625445     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.07.9665     Document Type: Article

References (58)

1. Williams ME, Densmore JJ: Biology and therapy of mantle cell lymphoma. Curr Opin Oncol 17:425-431, 2005
2. The Non-Hodgkin's Lymphoma Classification Project: A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 89:3909-3918, 1997
3. Argatoff LH, Connors JM, Klasa RJ, et al: Mantle cell lymphoma: A clinicopathologic study of 80 cases. Blood 89:2067-2078, 1997
4. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2006. CA Cancer J Clin 56:106-130, 2006
5. Boyle P, Ferlay J: Cancer incidence and mortality in Europe, 2004. Ann Oncol 16:481-488, 2005
6. Hiddemann W, Unterhalt M, Herrmann R, et al: Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: Results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. J Clin Oncol 16:1922-1930, 1998
7. Lenz G, Dreyling M, Hiddemann W: Mantle cell lymphoma: Established therapeutic options and future directions. Ann Hematol 83:71-77, 2004
8. Fisher RI: Mantle cell lymphoma: At last, some hope for successful innovative treatment strategies. J Clin Oncol 23:657-658, 2005
9. Bertoni F, Rinaldi A, Zucca E, et al: Update on the molecular biology of mantle cell lymphoma. Hematol Oncol 24:22-27, 2006
10. Bauwens D, Maerevoet M, Michaux L, et al: Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma. Br J Haematol 131:338-340, 2005
11. Romaguera JE, Fayad L, Rodriguez MA, et al: High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 23:7013-7023, 2005
12. Vigouroux S, Gaillard F, Moreau P, et al: High-dose therapy with autologous stem cell transplantation in first response in mantle cell lymphoma. Haematologica 90:1580-1582, 2005
13. Pott C, Schrader C, Gesk S, et al: Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood 107:2271-2278, 2006
14. Khouri IF, Romaguera J, Kantarjian H, et al: Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: An active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 16:3803-3809, 1998
15. Forstpointner R, Dreyling M, Repp R, et al: The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104:3064-3071, 2004
16. Lenz G, Dreyling M, Hosier E, et al: Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 23: 1984-1992, 2005
17. Howard OM, Gribben JG, Neuberg DS, et al: Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: Molecular complete responses are not predictive of progression-free survival. J Clin Oncol 20:1288-1294, 2002
18. Khouri IF, Lee MS, Saliba RM, et al: Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 21:4407-4412, 2003
19. Fisher RI, Dahlberg S, Nathwani BN, et al: A clinical analysis of two indolent lymphoma entities: Mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): A Southwest Oncology Group study. Blood 85:1075-1082, 1995
20. Witzig TE: Current treatment approaches for mantle-cell lymphoma. J Clin Oncol 23:6409-6414, 2005
21. Leonard JP, Schattner EJ, Coleman M: Biology and management of mantle cell lymphoma. Curr Opin Oncol 13:342-347, 2001
22. Bogner C, Peschel C, Decker T: Targeting the proteasome in mantle cell lymphoma: A promising therapeutic approach. Leuk Lymphoma 47:195-205, 2006
23. Pham LV, Tamayo AT, Yoshimura LC, et al: Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 171:88-95, 2003
24. Fu L, Lin-Lee YC, Pham LV, et al: Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas. Blood 107:4540-4548, 2006
25. Greiner TC, Dasgupta C, Ho VV, et al: Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma. Proc Natl Acad Sci U S A 103:2352-2357, 2006
26. Chiarle R, Budel LM, Skolnik J, et al: Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood 95:619-626, 2000
27. Rajkumar SV, Richardson PG, Hideshima T, et al: Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 23:630-639, 2005
28. Voorhees PM, Dees EC, O'Neil B, et al: The proteasome as a target for cancer therapy. Clin Cancer Res 9:6316-6325, 2003
29. Myung J, Kim KB, Crews CM: The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev 21:245-273, 2001
30. Adams J: The proteasome: A suitable antineoplastic target. Nat Rev Cancer 4:349-360, 2004
31. Perez-Galan P, Roue G, Villamor N, et al: The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 107:257-264, 2006
32. Pastore A, Rieken M, Weigert O, et al: Inhibition of proteasome is associated with early alterations of cell cycle regulators and induces synergistic antitumour activities in mantle cell lymphoma in a sequence dependent manner. Blood 106:677a, 2005 (abstr 2409)
33. Weinkauf M, Rieken M, Pastore A, et al: Altered cellular protein levels of tumor suppressor genes and heat shock elements (TRAP1) indicate sensitivity to the proteasome inhibitor bortezomib (Velcade) in mantle cell lymphoma. Blood 106:681a, 2005 (abstr 2424)
34. Goy A, Younes A, McLaughlin P, et al: Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 23:667-675, 2005
35. O'Connor OA, Wright J, Moskowitz C, et al: Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 23:676-684, 2005
36. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al: Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20:4420-4427, 2002
37. Strauss SJ, Maharaj L, Hoare S, et al: Bortezomib therapy in patients with relapsed or refractory lymphoma: Potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol 24:2105-2112, 2006
38. Belch A, Kouroukis C, Crump M, et al: Phase II trial of bortezomib in mantle cell lymphoma. Blood 104:175a, 2004 (abstr 608)
39. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol 17:1244-1253, 1999
40. Cheson BD, Pfistner B, Juweld ME, et al: Recommendations for revised response criteria for malignant lymphoma. J Clin Oncol 24:423s, 2006 (abstr 7507)
41. O'Connor O, Wright J, Moskowitz C, et al: Targeting the proteasome pathway with bortezomib in patients with mantle cell (MCL) and follicular lymphoma (FL) produces prolonged progression free survival among responding patients: Results of a multicenter phase II experience. Ann Oncol 16:66, 2005 (abstr 99)
42. Coiffier B, Haioun C, Ketterer N, et al: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 92:1927-1932, 1998
43. Kouroukis CT, Belch A, Crump M, et al: Flavopiridol in untreated or relapsed mantle-cell lymphoma: Results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21:1740-1745, 2003
44. Dumontet C, Morschhauser F, Solal-Celigny P, et al: Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma. Br J Haematol 113:772-778, 2001
45. Tobinai K, Watanabe T, Ogura M, et al: Phase II study of oral fludarabine phosphate in relapsed indolent B-Cell non-Hodgkin's lymphoma. J Clin Oncol 24:174-180, 2006
46. Decaudin D, Bosq J, Tertian G, et al: Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas. J Clin Oncol 16:579-583, 1998
47. Foran JM, Rohatiner AZ, Cunningham D, et al: European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 18:317-324, 2000
48. Ghielmini M, Schmitz SF, Cogliatti S, et al: Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: A study of the Swiss Group for Clinical Cancer Res (SAKK). J Clin Oncol 23:705-711, 2005
49. Witzig TE, Geyer SM, Ghobrial I, et al: Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 23: 5347-5356, 2005
50. Richardson PG, Barlogie B, Berenson J, et al: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617, 2003
51. Richardson PG, Sonneveld P, Schuster MW, et al: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487-2498, 2005
52. Jagannath S, Barlogie B, Berenson J, et al: A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 127: 165-172, 2004
53. Richardson PG, Briemberg H, Jagannath S, et al: Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24:3113-3120, 2006
54. Lonial S, Richardson P, Sonneveld P, et al: Hematologic profiles in the phase 3 APEX trial. Blood 106:970a, 2005 (abstr 3474)
55. Lonial S, Waller EK, Richardson PG, et al: Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 106:3777-3784, 2005
56. Leonard JP, Furman RR, Cheung Y-K, et al: Phase I/II trial of bortezomib + CHOP-rituximab in diffuse large B cell (DLBCL) and mantle cell lymphoma (MCL): Phase I results. Blood 106:147a, 2005 (abstr 491)
57. Drach J, Kaufmann H, Pichelmayer O, et al: Marked activity of bortezomib, rituximab, and dexamethasone (BORID) in heavily pretreated patients with mantle cell lymphoma. J Clin Oncol 24:681s, 2006 (suppl; abstr 17522)
58. Wiestner A, Dunleavy K, Rizzatti EG, et al: Potent single agent activity and tumor selectivity of bortezomib in mantle cell lymphoma: First impressions from a randomized phase II study of EPOCH-rituximab-bortezomib in untreated mantle cell lymphoma. Blood 106:266b, 2005 (abstr)